Skip to content

Mechanism and clinical study of low-intensity extracorporeal shock wave therapy in the treatment of erectile dysfunction

Mechanism and clinical study of low-intensity extracorporeal shock wave therapy in the treatment of erectile dysfunction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050411
Enrollment
Unknown
Registered
2021-08-27
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction (ED)

Interventions

Experimental group :Low-intensity extracorporeal shock wave therapy
Control group:Simulated treatment with pseudo shock wave probe
Single arm verification group:Low-intensity extracorporeal shock wave therapy

Sponsors

He'nan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients with vascular ED who have tried sexual life within the last 4 weeks, and the erectile function specific score (IIEF-EF) is less than or equal to 25 points. NPTR monitoring for 2 nights, vascular ED patients with number of erections <1 or head hardness <60% or erection duration less than 10 minutes. 2. Have a medical history of more than 6 months, have a relatively fixed sexual partner, and maintain a normal sexual relationship with their spouse during at least the last 6 months during the study. 3. Reproductive hormone testing is normal. 4. The informed consent of the patients has been signed, the compliance is good, and the follow-up can be completed on time.

Exclusion criteria

Exclusion criteria: 1. Those with congenital malformations and anatomical abnormalities of the genitals that significantly affect penile erection. 2. History of alcoholism or drug abuse. 3. Severe cardiovascular and cerebrovascular diseases, not suitable for sexual life. 4. Diabetic patients with uncontrolled blood sugar. 5. A history of mental or neurological disease. 6. Patients with Peyronie's disease, those with ulcers, tumors and other lesions at the treatment site.

Design outcomes

Primary

MeasureTime frame
Vascular endothelial growth factor;Angiopoitin-1;Angiopoitin-2;Brain-derived neurotrophic factor;Circulating endothelial progenitor cells;

Countries

China

Contacts

Public ContactZhang Xiangsheng

He'nan University People's Hospital, He'nan Provincial People's Hospital

zxs9818@126.com+86 13608698515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026